Merus to Participate in a Fireside Chat at the 23rd Annual Needham Virtual Healthcare Conference
Merus to Participate in a Fireside Chat at the 23rd Annual Needham Virtual Healthcare Conference
UTRECHT, The Netherlands and CAMBRIDGE, Mass., April 03, 2024 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics and Triclonics), today announced that Bill Lundberg, M.D., President, Chief Executive Officer of Merus, will participate in in a fireside chat at the 23rd Annual Needham Virtual Healthcare Conference on Wednesday, April 10, 2024 at 8:45 a.m. ET.
荷兰乌得勒支和马萨诸塞州剑桥，2024年4月3日（GLOBE NEWSWIRE）——开发创新的全长多特异性抗体的临床阶段肿瘤公司Merus N.V.（纳斯达克股票代码：MRUS）（Biclonics 和 Triclonics），今天宣布，Merus总裁兼首席执行官比尔·伦德伯格医学博士将在美国东部时间2024年4月10日星期三上午8点45分参加第23届尼德姆年度虚拟医疗会议的炉边谈话。
The webcast of the presentation will be contemporaneously available on the Investors page of the Company's website. The archived presentation will also be available there for a limited time after the event.
演讲的网络直播将同时在公司网站的投资者页面上播出。存档的演示文稿也将在活动结束后的限定时间内在那里提供。
About Merus
Merus is a clinical-stage oncology company developing innovative full-length human bispecific and trispecific antibody therapeutics, referred to as Multiclonics. Multiclonics are manufactured using industry standard processes and have been observed in preclinical and clinical studies to have several of the same features of conventional human monoclonal antibodies, such as long half-life and low immunogenicity. For additional information, please visit Merus' website, X and LinkedIn.
关于梅鲁斯
Merus 是一家临床阶段的肿瘤学公司，开发创新的全长人双特异性和三特异性抗体疗法，称为 Multiclonics。Multiclonics 采用行业标准工艺制造，在临床前和临床研究中观察到其具有与传统人类单克隆抗体相同的几种特征，例如半衰期长和免疫原性低。欲了解更多信息，请访问梅鲁斯的网站、X 和 LinkedIn。
Multiclonics, Biclonics and Triclonics are registered trademarks of Merus N.V.
Multiclonics，Biclonics 和 Triclonics 是 Merus N.V. 的注册商标
CONTACT: Investor and Media Inquiries: Sherri Spear Merus N.V. VP Investor Relations and Corporate Communications 617-821-3246 s.spear@merus.nl Kathleen Farren Merus N.V. IR/Corp Comms 617-230-4165 k.farren@merus.nl
联系人：投资者和媒体查询：Sherri Spear Merus N.V. 投资者关系和企业传播副总裁 617-821-3246 s.spear@merus.nl Kathleen Farren Merus N.V. ir/Corp Comms 617-230-4165 k.farren@merus.nl
译文内容由第三方软件翻译。